A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria:

• Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC),peritoneal primary carcinoma, or fallopian tube cancer.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Life expectancy of at least 12 weeks.

• Adequate hematological, liver, renal and neurologic functions.

• For participants who receive therapeutic anticoagulation: stable anticoagulantregimen.

• Enrollment between 1 and 12 weeks after initial surgery is performed for thecombined purpose of diagnosis, staging, and cytoreduction

Exclusion Criteria:

• Current diagnosis of borderline epithelial ovarian tumor or recurrent invasiveepithelial ovarian, primary peritoneal, or fallopian tube cancer treated withsurgery only.

• Prior radiotherapy to any portion of the abdominal cavity or pelvis.

• Prior chemotherapy for any abdominal or pelvic tumor, including neoadjuvantchemotherapy for ovarian, primary peritoneal, or fallopian tube cancer.

• Any prior targeted therapy (including, but not limited to, vaccines, antibodies, ortyrosine kinase inhibitors) or hormonal therapy for management of their epithelialovarian or peritoneal primary cancer.

• Synchronous primary endometrial cancer.

• Have a prior history of primary endometrial cancer, except: Stage not greater thanStage IB; no more than superficial myometrial invasion, without vascular orlymphatic invasion; no poorly differentiated subtypes, including papillary serous,clear cell, or other International Federation of Gynecological Oncologists (FIGO)Grade 3 lesions.

• Cancer present within the last 5 years with the exception of non-melanoma-relatedskin cancers and other specific malignancies or whose previous cancer treatmentcontraindicates study treatment.

• Active hepatitis B virus (HBV) infection (chronic or acute) or active hepatitis Cvirus (HCV) infection.

• Serious non-healing wounds, ulcers, or bone fractures.

• Patients with clinically significant cardiovascular disease.

• Have known hypersensitivity to Chinese hamster ovary cell products or otherrecombinant human or humanized antibodies.

• Have known sensitivity to any component of paclitaxel.

• Undergo major surgical procedure within 28 days prior to randomization oranticipated during the course of the study.

• Have core biopsy or other minor surgical procedures within 7 days prior to the firstdose of bevacizumab/placebo.

• History or evidence of thrombotic disorders within the last 6 months prior toenrollment.